SCHEMBL2864626

SCHEMBL2864626

O=C1OC(c2ccccc2)(c2ccccc2)N2C1CNCC2C(=O)N1CCc2ccccc2C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.41
ALDH1A1 P00352 3/20 0.40
HPGD P15428 3/20 0.40
THRB P10828 1/20 0.40
CPT2 P23786 1/20 0.39
CPT1A P50416 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
KDM4E B2RXH2 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
GAA P10253 1/20 0.38
NOTUM Q6P988 1/20 0.38
HSD11B1 P28845 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2868928 0.83 NPSR1 (0.41) ALDH1A1NPSR1KMT2APOLB
SCHEMBL2865817 0.82 ALDH1A1 (0.47) ALDH1A1HPGDKDM4EGAAMEN1
SCHEMBL2863242 0.79 HRH3 (0.44) NPSR1GAAL3MBTL1TP53SMN1; SMN2
SCHEMBL2863393 0.78 CHRM2 (0.41) NPSR1KDM4EATM
SCHEMBL2862412 0.77 LMNA (0.42) ALDH1A1NPSR1TDP1NOTUMMEN1
SCHEMBL2861714 0.76 NPSR1 (0.40) NPSR1POLB
SCHEMBL2856555 0.75 NPSR1 (0.38) ALDH1A1NPSR1L3MBTL1SMN1; SMN2POLB
SCHEMBL2871903 0.74 NPSR1 (0.40) NPSR1TDP1GAAKMT2ASMN1; SMN2
SCHEMBL2862082 0.74 HTR4 (0.43) NPSR1POLB
SCHEMBL2865537 0.74 ALDH1A1 (0.40) ALDH1A1HPGDMEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 KEAP1 918/4885ALDH1A1 2926/4885HPGD 1412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.